Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01508702




Registration number
NCT01508702
Ethics application status
Date submitted
10/01/2012
Date registered
12/01/2012
Date last updated
12/02/2016

Titles & IDs
Public title
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Scientific title
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Secondary ID [1] 0 0
2011-003756-39
Secondary ID [2] 0 0
RDEA594-303
Universal Trial Number (UTN)
Trial acronym
LIGHT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gout 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - lesinurad
Treatment: Drugs - Placebo

Experimental: lesinurad 400 mg -

Placebo Comparator: placebo -


Treatment: Drugs: lesinurad
Tablets, 400 mg QD

Treatment: Drugs: Placebo
Tablets, Placebo QD
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects With an sUA Level That is < 6.0 mg/dL
Timepoint [1] 0 0
6 months

Eligibility
Key inclusion criteria
- Subject is able to understand the study procedures, the risks involved and willing to
provide written informed consent before the first study related activity.

- Subject meets the diagnosis of gout as per the American Rheumatism Association
Criteria for the Classification of Acute Arthritis of Primary Gout.

- Subject has an sUA level = 6.5 mg/dL at the Screening and Day -7 Visits.

- Subject must be able to take gout flare prophylaxis with colchicine or NSAID
(including Cox-2 selective NSAID) ± PPI.

- Subject has a history (either by medical record or subject interview) of intolerance
or a contraindication to either allopurinol or febuxostat.

- Body mass index (BMI) < 45 kg/m2
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subject who is taking any other approved urate-lowering medication that is indicated
for the treatment of gout at the Screening Visit.

- Subject with a documented history or suspicion of kidney stones.

- Subject who is pregnant or breastfeeding.

- Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150
mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).

- Subject with a history or suspicion of drug abuse within the past 5 years.

- Subject that requires or may require systemic immunosuppressive or immunomodulatory
treatment.

- Subject with a known or suspected human immunodeficiency virus (HIV) infection.

- Subject with a positive test for active hepatitis B or hepatitis C infection.

- Subject with a history of malignancy within the previous 5 years with the exception of
non-melanoma skin cancer that has been treated with no evidence of recurrence, treated
cervical dysplasia or treated in situ Grade 1 cervical cancer.

- Subject within the last 12 months with: unstable angina, New York Heart Association
class III or IV heart failure, myocardial infarction, stroke, or deep venous
thrombosis; or subjects currently receiving anticoagulants.

- Subject with uncontrolled hypertension.

- Subject with an estimated creatinine clearance < 30 mL/min.

- Subject with active peptic ulcer disease requiring treatment.

- Subject with active liver disease, or hepatic dysfunction.

- Subject receiving chronic treatment with more than 325 mg salicylates per day.

- Subject taking valpromide, progabide, or valproic acid.

- Subject who has received an investigational therapy within 8 weeks or 5 half-lives
(whichever is longer) prior to the Screening Visit.

- Subject with any other medical or psychological condition, which in the opinion of the
Investigator and/or Medical Monitor, might create undue risk to the subject or
interfere with the subject's ability to comply with the protocol requirements, or to
complete the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2013
Sample size
Target
Accrual to date
Final
214
Recruitment in Australia
Recruitment state(s)
QLD,TAS
Recruitment hospital [1] 0 0
- Butterfield
Recruitment hospital [2] 0 0
- Hobart
Recruitment hospital [3] 0 0
- Tasmania
Recruitment postcode(s) [1] 0 0
4029 - Butterfield
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
7000 - Tasmania
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Florida
Country [8] 0 0
United States of America
State/province [8] 0 0
Georgia
Country [9] 0 0
United States of America
State/province [9] 0 0
Hawaii
Country [10] 0 0
United States of America
State/province [10] 0 0
Idaho
Country [11] 0 0
United States of America
State/province [11] 0 0
Illinois
Country [12] 0 0
United States of America
State/province [12] 0 0
Kentucky
Country [13] 0 0
United States of America
State/province [13] 0 0
Louisiana
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
North Dakota
Country [21] 0 0
United States of America
State/province [21] 0 0
Ohio
Country [22] 0 0
United States of America
State/province [22] 0 0
Oklahoma
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
South Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Tennessee
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Utah
Country [28] 0 0
United States of America
State/province [28] 0 0
Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Washington
Country [30] 0 0
United States of America
State/province [30] 0 0
West Virginia
Country [31] 0 0
Belgium
State/province [31] 0 0
Brussels
Country [32] 0 0
Belgium
State/province [32] 0 0
Limburg
Country [33] 0 0
Belgium
State/province [33] 0 0
Gozee
Country [34] 0 0
Belgium
State/province [34] 0 0
Kortrijk
Country [35] 0 0
Belgium
State/province [35] 0 0
Yvoir
Country [36] 0 0
Canada
State/province [36] 0 0
British Columbia
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Germany
State/province [39] 0 0
Saxony
Country [40] 0 0
Germany
State/province [40] 0 0
Dresden
Country [41] 0 0
New Zealand
State/province [41] 0 0
Bay of Plenty
Country [42] 0 0
New Zealand
State/province [42] 0 0
Auckland
Country [43] 0 0
South Africa
State/province [43] 0 0
Durban
Country [44] 0 0
South Africa
State/province [44] 0 0
Pretoria
Country [45] 0 0
South Africa
State/province [45] 0 0
Rondebosch
Country [46] 0 0
South Africa
State/province [46] 0 0
Stellenbosch
Country [47] 0 0
South Africa
State/province [47] 0 0
Thabazimbi

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ardea Biosciences, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will assess the serum uric acid lowering effects and safety of lesinurad compared
to placebo in patients who are intolerant or have a contraindication to allopurinol or
febuxostat.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01508702
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Chris Storgard, MD
Address 0 0
Ardea Biosciences, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01508702